The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...

Transaction value based on SEC Form 4 weighted average purchase price ($21.16); post-transaction value calculated using Jan. 22, 2026 market close. CareDx is a healthcare diagnostics company ...

SOUTH SAN FRANCISCO, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of ...

The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value ...

We recently compiled a list of the 10 Best Organ Transplant and Diagnosis Stocks To Buy Now. In this article, we are going to take a look at where CareDx, Inc (NASDAQ:CDNA) stands against the other ...

CareDx will acquire Naveris, a commercial stage precision oncology diagnostics company, for an upfront payment of $160 million in cash. The deal also includes up to an additional $100 million in ...

CareDx offers diagnostic solutions for transplant patients, including AlloSure (kidney, heart, lung), AlloMap Heart, TruSight HLA, Olerup SSP, QTYPE, Ottr software, AlloSeq product line, and patient ...